# Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer

> **NCT03532087** · PHASE2 · WITHDRAWN · sponsor: **Borstkanker Onderzoek Groep**

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Denosumab 120 mg
- **DRUG:** Denosumab 60 mg

## Key facts

- **NCT ID:** NCT03532087
- **Lead sponsor:** Borstkanker Onderzoek Groep
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-02
- **Primary completion:** 2021-02
- **Final completion:** 2023-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to new insights
- **Last updated:** 2020-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03532087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03532087, "Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03532087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*